

Escherichia coli from clinical mastitis: serotypes and virulence factors

José Benedito C. Fernandes, Larissa G. Zanardo, Newton N. Galvão, Isabel A. Carvalho, Luis Augusto Nero, Maria Aparecida S. Moreira¹

Abstract. In the current study, the virulence factors in *Escherichia coli* isolates from bovine mastitis were investigated, and the connection between these factors and infection was evaluated using phenotypic and genotypic analyses. Twenty-seven *E. coli* isolates were analyzed, and 2 were shown to produce verotoxin. All isolates had the ability to produce biofilms, although at different levels. One isolate was found to be sensitive to the bactericidal activity of bovine serum, 11 were intermediate, and 15 were resistant. Some isolates showed resistance to trimethoprim sulfa (9) and ampicillin (4), intermediate resistance to neomycin (1) and trimethoprim sulfa (5), and simultaneous resistance to ampicillin and trimethoprim sulfa (4). The *fimH* gene was found in all isolates and was associated with other virulence markers: *pap* (1), *stb* (8), *cs31a* (3), *stb* and *vt2* (2), *cs31a* and *stb* (3), *east1* and *kps* (1), *stb* and *east1* (1), *cs31a* and *east1* (1), and *cs31a*, *stb*, *pap*, and *iucD* (1). Serogroups were determined for 3 isolates: O93:H4, O83:H19, and O15:H11. Phylogenetic analysis showed that 23 isolates belonged to group A and 4 belonged to B1. The findings revealed that these *E. coli* isolates are opportunistic pathogens with different virulence factors. The results indicate that the pathogenicity route of *E. coli* in bovine mastitis is not a consequence of 1 specific virulence factor.

Key words: *Escherichia coli*; mastitis; milk; polymerase chain reaction; virulence factor.

Introduction

Bovine mastitis is one of the most complex and costly diseases in the dairy industry due to its high prevalence and economic losses.³⁹ There is also a potential risk to public health because it may transmit zoonoses and food toxin infections.⁹ Mastitis triggered by *Escherichia coli* is usually sporadic, and clinical signs vary from very severe or even fatal forms to mild mastitis⁴¹ in which cows have only local signs in the udder. While the severity of the disease depends on host immune response and genetic makeup (“cow factors”),¹¹ virulence of the bacterial strain involved may also play a role.

The *E. coli* strain that causes mastitis can potentially form a new putative pathotype, mammary pathogenic *E. coli*,⁴¹ and make use of the same pathogenesis scheme used by other extraintestinal pathogenic *E. coli* (ExPEC). There are, however, many publications on the absence of known ExPEC virulence-associated genes and intestinal pathogenic *E. coli* among *E. coli* mastitis isolates, which indicates that there may be different ways to cause mastitis.⁴¹

Several virulence factors have been detected in pathogenic *E. coli*. These include toxins, adhesins, invasins, capsule production, the ability to resist serum complement, and iron scavenging. Only isolates with successful combinations of virulence factors will be capable of causing disease.²⁵ Bovine mastitis resembles a urinary infection in that the infection ascends and is caused by bacteria from the environment. Bacterial virulence factors are required to fight the host's selection pressure and for the bacteria to colonize,

multiply and survive in the udder.²⁴ The difficulties of treating recurrent infections might be related to the ability of pathogens to form biofilms, although little research exists on biofilms in animals.²⁸

Considering the losses resulting from this disease, the recognition of *E. coli* as a highly adaptive organism in different niches, the inefficiency of treatment, and the impact of this infective agent on public health, the present study aimed to investigate the presence of virulence factors in *E. coli* isolates from bovine mastitis in an attempt to correlate these characteristics and establish a possible connection with mastitis.

Material and methods

Escherichia coli isolates and serology

The current study involved 7 dairy farms located in the Viçosa and Juiz de Fora regions in the State of Minas Gerais, Brazil. Mastitis was defined by classical symptoms. All cows with symptoms of acute clinical environmental mastitis were

From Setor de Medicina Veterinária Preventiva e Saúde Pública, Departamento de Veterinária, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.

¹Corresponding Author: Maria Aparecida S. Moreira, Laboratório de Doenças Bacterianas, Setor de Medicina Veterinária Preventiva e Saúde Pública, Departamento de Veterinária, Universidade Federal de Viçosa, Av. P. H. Rolfs s/n, Viçosa, Minas Gerais 36570-000, Brazil. masm@ufv.br

examined by veterinarians who diagnosed the illness. Animals showed repetitive episodes of illness, without death. One pooled milk sample was aseptically collected once from each selected animal, yielding a total of 27 samples. The collections were performed before treatment with antibiotics. One *E. coli* isolate was obtained from each sample using a previously published protocol.²² The samples and controls were kept in brain heart infusion (BHI)^a with glycerol (10%) at -80°C until analysis. Each culture was streaked onto BHI agar plates (37°C for 24 hr), and a single colony was inoculated in BHI and incubated at 37°C by shaking until achieve turbidity similar to tube 1 on the McFarland scale, corresponding to approximately 3×10^8 colony forming units per ml (CFU/ml). All isolates were submitted to serological testing using somatic (O1-O172) and flagellar (H1-H50) antisera as previously described.¹⁹

Verotoxin production

The cultures were analytically tested to verify verotoxin production using a previously described method³⁶ with some modification of the use of essential medium,^b with 1.6 mg/l penicillin, 0.4 mg/l streptomycin, and 5% fetal bovine serum.^b The morphological changes were evaluated at 24 and 48 hr of incubation. Verotoxin-producing isolates were characterized by initial cell rounding and shrinkage, followed by loss of cell viability. The positive controls used were *E. coli* O157:H7^c and *E. coli* J2^d for *vt1* and *vt2* genes, respectively.

Antimicrobial resistance

The disc diffusion method,³ with modifications described by the Clinical and Laboratory Standards Institute (CLSI),¹⁵ was performed with antimicrobials most prescribed by veterinarians working in regions where the samples were collected: ampicillin and gentamicin (10 μg each), trimethoprim sulfa (25 μg), neomycin, cephalixin, ceftiofur, and florfenicol (30 μg each), and cefoperazone (75 μg). The zones of inhibition were measured, taken as the average of triplicates, and compared with the break points presented in the Table 1, adapted from CLSI.^{14,15} The quality control strain used was *E. coli* American Type Culture Collection (ATCC) 25922.

Resistance to lytic activity of serum complement

A turbidimetric assay³³ was employed to test the resistance of the cultures to serum bactericidal activity. *Escherichia coli* strain J-96 was used as the positive control. The isolates that showed optical density at 630 nm (OD_{630}) values below 50% of the initial value were considered sensitive to the bactericidal activity. Isolates with OD_{630} values above 90% of the initial value were considered resistant, and those that remained between these values were considered intermediate.

Table 1. Antimicrobials, concentrations, and interpretation of inhibition zones for the evaluation of susceptibility patterns of *Escherichia coli*.

Antimicrobial	Concentration (μg)	Diameter of inhibition zone (mm)		
		Resistant	Intermediate	Sensitive
Neomycin*	30	≤ 12	13–16	≥ 17
Gentamicin†	10	≤ 12	13–14	≥ 15
Cefoperazone*	75	≤ 15	16–20	≥ 21
Cephalexin*	30	≤ 14	15–17	≥ 18
Ceftiofur†	30	≤ 17	18–20	≥ 21
Ampicillin†	10	≤ 13	14–16	≥ 17
Florfenicol†	30	≤ 14	15–18	≥ 19
Trimethoprim sulfa†	25	≤ 10	11–15	≥ 16

*Adapted from Clinical and Laboratory Standards Institute.¹⁴

†Adapted from Clinical and Laboratory Standards Institute.¹⁵

Biofilm production

Quantification of biofilm production in plastic microplates was performed as previously described.⁴³ The OD_{570} of each well was measured using a microplate reader,^c and the means of the triplicates were calculated. The isolates were classified as non-producers, weak, moderate, or strong biofilm producers based on OD of the isolates and the average OD_{570} of the negative control, according to the methodology used.⁴³ Briefly, the cut-off OD (ODc) was defined as 3 standard deviations above the mean OD of the negative control. Strains were classified as follows: $\text{OD} \leq \text{ODc}$ = no biofilm producer, $\text{ODc} < \text{OD} \leq 2 \text{ODc}$ = weak biofilm producer, $2 \text{ODc} < \text{OD} \leq 4 \text{ODc}$ = moderate biofilm producer, and $4 \text{ODc} < \text{OD}$ = strong biofilm producer.

Polymerase chain reaction

Virulence marker genes were detected by polymerase chain reaction (PCR) at the Laboratory of Bacterial Antigens II, Department of Microbiology and Immunology, Instituto de Biologia, Universidade Estadual de Campinas (Campinas, São Paulo, Brazil; Table 2). The major *E. coli* phylogenetic groups (A, B1, B2, and D) were determined by triplex PCR as described previously.¹³

Results

Only 2 cultures, *E. coli* 25 and 3888, showed an ability to produce verotoxins, which was confirmed by the presence of the *vt2* gene. For these cultures, initial cell shrinkage and rounding, followed by loss of cell viability was observed. The most significant cytotoxic effects were observed at the lowest filtered dilution and at 48 hr of incubation.

The ability to form biofilms *in vitro* was detected in all of the isolates, but at different levels of production. Five isolates

Table 2. Genes, phenotypes, primer sequences, size of amplified products (bp), control strains, and references used in the polymerase chain reaction in the current study.

Gene	Description/Function	Sequence 5'-3'	Product (bp)	Control strain	Reference
Colonization factors					
<i>fimH</i>	Type I fimbriae	TGCAGAACGGATAAGCCGTGG GCAGTACCTGCCCTCCGGTA	508	ORN115	23
<i>f5</i>	F5 fimbriae	TGGGACTACCAATGCTTCTG TATCCACCATTAGACGGAGC	450	B41 (O101:K ⁻)	35
<i>f41</i>	F41 fimbriae	GAGGGACTTTCATCTTTTAG AGTCCATTCCATTTAATGGC	431	B41 (O101:K ⁻)	21
<i>cs31a</i>	Coli surface-associated	GGGCGCTCTCCTTCAAC CGCCCTAATTGCTGGCGAC	402	31A	5
<i>f17</i>	F17 fimbriae	GCAGAAAATTCAATTTATCCTTGG CTGATAAGCGATGGTGAATTAAC	537	B62	5
<i>f165</i>	F165 fimbriae	GGCAGTGGTGTCTTTGGTG GGCCAGTAAAAGATAATTGAACC	277	PR-4787 0155:H ⁺ :K165 ⁺	23
<i>eae</i>	Intimin	GACCCGGCACAAGCATAAGC CCACCTGCAGCAACAAGAGG	384	2348/69	47
Toxins					
<i>sta</i>	Heat-stable enterotoxin a	TCCGTGAAACAACATGACGG ATAACATCCAGCACAGGCAG	244	B41 (O101:K ⁻)	42
<i>stb</i>	Heat-stable enterotoxin b	ATCGCATTTCTTCTTGCATC GGGCGCCAAAGCATGCTCC	172	B41M	8
<i>lt1</i>	Heat labile toxin I	GGCGACAGATTATACCGTGC CCGAATTCTGTTATATATGTC	696	40T	38
<i>lt2</i>	Heat labile toxin II	AGATATAATGATGGATATGTATC TAACCCTCGAAATAAATCTC	300	Pc/c LT-II	38
<i>east1</i>	EaggEC heat-stable enterotoxin	CCATCAACACAGTATATCCGA GGTCGCGAGTGACGGCTTGT	111	FV171: (O44)	46
<i>vt1</i>	Verotoxin I	AAGTTGCAGCTCTCTTTGAATA TGCAAACAAATTATCCCCTGAG	364	152-2(5)(O157:H7)	31
<i>vt2</i>	Verotoxin II	GGGCAGTTATTTTGTGTGGA GTATCTGCCTGAAGCGTAA	386	152-2(5)(O157:H7)	31
<i>cnf</i>	Cytotoxic necrotizing factor	CTGGACTCGAGGTGGTGG CTCCTGTCAACCACAGCC	533	MR 48 (O75:K95)	7
<i>cldt</i>	Cytolethal distending toxin	AAACAGGACGGTAATAATGACTAATA GTGATCTCCTCCATGAAAAATAGT	2231	CDT III (O128:H ⁻)	12
Extraintestinal					
<i>pap</i>	P fimbriae	GCAACAGCAACGCTGGTTGCATCAT AGAGAGAGCCACTCTTATACGGACA	336	J96	45
<i>afa</i>	Afimbrial adhesin	GCTGGGCAGCAAACTATAACTCTC CATCAAGCTGTTTGTTCGTCGCCG	750	FV35	45
<i>sfa</i>	S Fimbriae	CGGAGGAGTAATTACAAACCTGGCA CTCCGGAGAAGTGGGTGCATCTTAC	410	FVL2	16
<i>iucD</i>	Aerobactin biosynthesis	TACCGGATTGTCATATGCAGACCGT AATATCTTCCTCCAGTCCGGAGAAG	602	FVL8	45
<i>saa</i>	STEC autoagglutinating adhesin	CGTGATGAACAGGCTATTGC ATGGACATGCCTGTGGCAAC	119	FVL8	32
<i>ehly</i>	Enterohemolysin	GCATCATCAAGCGTACGTTCC AATGAGCCAAGCTGGTTAAGCT	534	C3888: Ehly+	32
<i>hly</i>	Hemolysin	AACAAGGATAAGCACTGTTCTGGCT ACCATATAAGCGGTCAATCCCGTCA	1177	FVL 16 (O6:K13:H1)	45
Other					
<i>kps</i>	Capsular polysaccharide	GCGCATTTGCTGATACTGTTG CATCAGACGATAAGCATGAGCA	272	U9-41	23
<i>ipaH</i>	Invasion plasmid	GTTCCCTTGACCGCCTTTCGGATACCGTC GCCGGTCAGCCACCCTCTGAGATAC	424	EIEC	40

Table 3. Virulence markers, serology, and phylogenic groups of *Escherichia coli* isolates obtained from mastitic milk in the current study.

Isolate	Serogroup	Production of biofilms	Profile of resistance			Resistance to serum	Verotoxin	Phylogeny
			Ampicillin	Neomycin	Trimethoprim sulfa			
1	ONT*:H2	S§	S¶	S	I††	R	-‡‡	A
2	ONT:H23	M‡	S	S	S	R	-	B1
3E	ONT:H23	M	S	S	S	R	-	B1
3H	ONT:H23	W#	S	S	I	R	-	A
4	ONT:HN†	M	S	S	I	R	-	A
5	O12:HNT	W	S	S	S	I	-	A
23	ONT:H48	W	S	S	S	I	-	A
24	ONT:H48	M	S	S	S	I	-	A
25	OR‡:HNT	W	S	S	S	I	+§§	A
26	Nontypable	M	S	S	S	R	-	A
27	Nontypable	W	S	S	S	R	-	A
29	Nontypable	W	S	S	S	I	-	A
30	O93:H4	W	R**	I	R	I	-	A
39	ONT:H20	W	S	S	S	R	-	A
51	ONT:H7	S	S	S	S	I	-	B1
53	OR:H21	S	S	S	S	I	-	A
54	OR:H7	S	S	S	S	S	-	B1
219	ONT:H9	M	S	S	I	I	-	A
2058	ONT:HNM	W	S	S	R	R	-	A
3397	O83:H19	W	S	S	I	I	-	A
3536	ONT:HNM	M	R	S	R	R	-	A
3888	ONT:H31	M	S	S	R	I	+	A
3889	O15:H11	M	S	S	R	R	-	A
3890	ONT:H19	M	R	S	R	R	-	A
3901	Nontypable	S	S	S	R	R	-	A
3922	ONT:HNM	M	S	S	R	R	-	A
3950	ONT:HNM	W	R	S	R	R	-	A

*Nontypable.
 †Not mobile.
 ‡Rough.
 §Strong biofilm producer.
 ‡Moderate biofilm producer.
 #Weak biofilm producer.
 ¶Sensitive.
 **Resistant.
 ††Intermediate.
 ‡‡Does not produce.
 §§Produces.

were considered as strong producers, 11 were moderate producers, and 11 were weak biofilm producers (Table 3). Among the tested antimicrobials, resistance was observed to trimethoprim sulfa (9) and ampicillin (4), and intermediate resistance was observed to neomycin (1) and trimethoprim sulfa (5). Four isolates were resistant to both ampicillin and trimethoprim sulfa (Table 3). According to the growth patterns observed in bovine serum, the isolates were divided into 3 groups depending on their resistance to lytic activity: sensitive, intermediate, and resistant. Only 1 isolate, *E. coli* 54, was sensitive, 11 were intermediate, and 15 were resistant (Table 3). Serotyping was only possible for 3 cultures,

which were identified as O93:H4, O83:H19, and O15:H11 (Table 3). Somatic antigen identification was possible for 4 isolates (O12, O15, O83, and O93), and flagellar identification was possible for 16 isolates (H2, H4, H7, H9, H11, H19, H20, H21, H23, H31, and H48). The flagellar antigen H23 was identified in 3 isolates, followed by H7, H19, and H48 in 2 isolates each, and the other flagellar serogroups were found in 1 isolate.

The *E. coli* isolates were classified in the following phylogenic groups: 23 isolates belonged to group A and 4 to group B1 (Table 3). The *fimH* gene was the only virulence-associated gene detected in all of the isolates. None of the

Table 4. Combinations of virulence markers detected in *Escherichia coli* isolates obtained from mastitic milk by polymerase chain reaction in the current study.

Combination of markers	No. of isolates	Isolate
<i>fimH</i>	6	4, 39, 219, 2058, 3901, 3922
<i>fimH, pap</i>	1	3536
<i>fimH, stb</i>	8	1, 26, 27, 29, 53, 3397, 3889, 3950
<i>fimH, cs31a</i>	3	2, 3E, 24
<i>fimH, stb, vt2</i>	2	25, 3888
<i>fimH, cs31a, stb</i>	3	3H, 23, 3890
<i>fimH, east1, kps</i>	1	5
<i>fimH, stb, east1</i>	1	54
<i>fimH, cs31a, east1</i>	1	51
<i>fimH, cs31a, stb, pap, iucD</i>	1	30
Total	27	

isolates had the genes for *f5, f41, f17, f165, eae, sta, lt1, lt2, cnf, cldt, pap, afa, sfa, saa, ehly, hly, or ipaH*. All of the remaining genes were detected in combination with *fimH* and others. The combination of *fimH* and *sta* genes was the most frequent, found in 8 isolates. Full details of the other gene combinations detected are presented in Table 4.

Discussion

In the current study, 7.5% (2/27) of the isolates were cytotoxic in Vero (African green monkey kidney epithelial) cell culture, confirmed by molecular detection of the *vt2* gene (Table 4). Earlier studies^{4,34} have also detected a low frequency of verotoxin producers obtained from mastitic milk and a greater predominance of the *vt2* gene in relation to *vt1*. Verotoxin-producing strains or Shiga toxin-producing are considered to be pathogenic to human beings if other factors are associated with this virulence.²⁶

Simultaneous resistance was observed for only 2 antibiotics, ampicillin and trimethoprim sulfa, in 14.8% of the isolates, a common resistance profile in *E. coli* isolates in other studies.^{27,37} In contrast, a high level of antimicrobial resistance to many antibiotics and an elevated number of multi-resistant strains among mastitis-associated *E. coli* strains have been reported in an earlier Brazilian study.³⁴ Similar reports of high levels of resistance to antimicrobials exist.^{1,27,37} The findings of the present study suggest that, on the properties sampled, there may not have been selective pressure caused by antibiotic use.

The current study found that 55.5% of the isolates were resistant to serum. However, the isolates with intermediate behavior (40.7%) may be considered as “potentially” serum-resistant, expanding the resistance profile to almost all of the isolates since only 1 was considered as authentically sensitive. An earlier study³⁰ found serum-resistant isolates (64%) and related the different values found in other studies to possible

variations in methodologies and serum concentrations used. There is disagreement in the literature on whether serum resistance is an important virulence factor in mastitis *E. coli* isolates and if there is a correlation between serum resistance and antimicrobial resistance.^{2,20,29} In the present study, no relationship between serum and antimicrobial resistance was observed.

Biofilms in animals are believed to be involved in many diseases, such as mastitis.²⁸ All of the tested isolates were able to produce biofilms in vitro. Recurrent clinical coliform mastitis can also occur as a result of the persistence of the organism within the mammary gland,¹⁰ and the production of biofilms can provide suitable conditions for the persistence of bacteria at this site.

Several studies have attempted to correlate virulence factors with the etiology of bovine mastitis.^{4,24} The results obtained in the present study showed a combination of different virulence factors in the *E. coli* isolates (Table 4). The most common adhesins found in both commensal and pathogenic *E. coli* isolates as well as in other enterobacteria are type 1 fimbriae (*fimH* gene), and these have influence on biofilm formation.⁴⁴ The finding was consistent with the current study, as the *fimH* gene was detected in all isolates studied.

An earlier study¹⁷ failed to detect virulence factors in *E. coli* associated with persistent bovine mastitis, among these the *stb* and *pap* genes, unlike the current study where both these genes were detected. The *cs31a* gene (afimbrial adhesin *cs31a*) has not been commonly detected in earlier studies of mastitis-linked *E. coli*.²⁴ In contrast, in the present study, this gene was detected in 8 out of 27 isolates. In the present work, only 3 isolates had the *east1* gene, a gene present in enteroaggregative *E. coli*⁸ as well as *E. coli* isolated from cattle with septicemia and diarrhea.⁵

The majority of isolates (24/27) in the present study belong to phylogenetic group A (Table 3), where most commensal strains are grouped.^{6,23} It was anticipated that the isolates of *E. coli* obtained from bovine mastitis milk would belong to group B2 or D, the virulent extraintestinal strain groups.^{6,23} Farm animal *E. coli* microbiota are characterized by a high proportion of A and B1 strains and a lower proportion of B2 and D strains.¹⁸

The results obtained in the present study indicate that the pathogenic role of *E. coli* in bovine mastitis is not a consequence of specific virulence factors. Based on the virulence factors examined, it was not possible to group these isolates into pathotypes able to cause mastitis. Further studies using other virulence factors are necessary to elucidate the relationship between the presence of these factors in *E. coli* isolates from mastitis and their classification in distinct pathotypes and to investigate commensal strains of *E. coli* as possible agents of mastitis.

Acknowledgements

The authors would like to thank Professor Domingos da Silva Leite (State University of Campinas) for kindly providing the control

strains of *E. coli* and the PCR analysis, Dr Maria Aparecida Vasconcelos Paiva Brito (Empresa Brasileira de Pesquisa Agropecuária) for providing the *E. coli* isolates from clinical mastitis, Professor Beatriz E. C. Guth (Universidade Federal de São Paulo) for help in serology, and Professor Rosa Maria Silva (Universidade Federal de São Paulo) for kindly providing the *E. coli* J96.

Sources and manufacturers

- a. Oxoid Ltd., Basingstoke, United Kingdom.
- b. Cultilab, Campinas, São Paulo, Brazil.
- c. Dr. J. M. Lord, University of Warwick, Coventry, United Kingdom.
- d. Dr. Y Takeda, Jiisen University, Tokyo, Japan.
- e. ELx800, BioTek Instruments Inc., Winooski, VT.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors would like to thank FAPEMIG (Fundação de Amparo a Pesquisa do Estado de Minas Gerais) for financing the publication of this article. Isabel A. Carvalho is supported by CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior), and Luis A. Nero is supported by CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico) and FAPEMIG.

References

1. Allen SE, Boerlin P, Janecko N, et al.: 2011, Antimicrobial resistance in generic *Escherichia coli* isolates from wild small mammals living in swine farm, residential, landfill, and natural environments in southern Ontario, Canada. *Appl Environ Microbiol* 77:882–888.
2. Barrow PA, Hill AW: 1989, The virulence characteristics of strains of *Escherichia coli* isolated from cases of bovine mastitis in England and Wales. *Vet Microbiol* 20:35–48.
3. Bauer AW, Kirby WM, Sherris JC, Turck M: 1966, Antibiotic susceptibility testing by a standardized single disk method. *Am J Clin Pathol* 45:493–496.
4. Bean A, Williamson J, Cursons RT: 2004, Virulence genes of *Escherichia coli* strains isolated from mastitic milk. *J Vet Med B Infect Dis Vet Public Health* 51:285–287.
5. Bertin Y, Martin C, Girardeau JP, et al.: 1998, Association of genes encoding P fimbriae, CS31A antigen and EAST 1 toxin among CNF1-producing *Escherichia coli* strains from cattle with septicemia and diarrhea. *FEMS Microbiol Lett* 162:235–239.
6. Bingen E, Picard B, Brahimi N, et al.: 1998, Phylogenetic analysis of *Escherichia coli* strains causing neonatal meningitis suggests horizontal gene transfer from a predominant pool of highly virulent B2 group strains. *J Infect Dis* 177:642–650.
7. Blanco M, Blanco JE, Alonso MP, et al.: 1997, Detection of pap, sfa and afa adhesin-encoding operons in uropathogenic *Escherichia coli* strains: relationship with expression of adhesins and production of toxins. *Res Microbiol* 148:745–755.
8. Blanco M, Blanco JE, Gonzalez EA, et al.: 1997, Genes coding for enterotoxins and verotoxins in porcine *Escherichia coli* strains belonging to different O:K:H serotypes: relationship with toxic phenotypes. *J Clin Microbiol* 35:2958–2963.
9. Blum S, Heller ED, Krifucks O, et al.: 2008, Identification of a bovine mastitis *Escherichia coli* subset. *Vet Microbiol* 132:135–148.
10. Bradley AJ, Green MJ: 2001, Adaptation of *Escherichia coli* to the bovine mammary gland. *J Clin Microbiol* 39:1845–1849.
11. Burvenich C, Van Merris V, Mehrzad J, et al.: 2003, Severity of *E. coli* mastitis is mainly determined by cow factors. *Vet Res* 34:521–564.
12. Clark CG, Johnson ST, Easy RH, et al.: 2002, PCR for detection of cdt-III and the relative frequencies of cytolethal distending toxin variant-producing *Escherichia coli* isolates from humans and cattle. *J Clin Microbiol* 40:2671–2674.
13. Clermont O, Bonacorsi S, Bingen E: 2000, Rapid and simple determination of the *Escherichia coli* phylogenetic group. *Appl Environ Microbiol* 66:4555–4558.
14. Clinical and Laboratory Standards Institute (CLSI): 2006, Performance standards for antimicrobial susceptibility testing, 16th informational supplement. CLSI document M100-S16. CLSI, Wayne, PA.
15. Clinical and Laboratory Standards Institute (CLSI): 2008, Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard—third edition. CLSI document M31-A3. CLSI, Wayne, PA.
16. Daigle F, Harel J, Fairbrother JM, Lebel P: 1994, Expression and detection of pap-, sfa-, and afa-encoded fimbrial adhesin systems among uropathogenic *Escherichia coli*. *Can J Microbiol* 40:286–291.
17. Dogan B, Klaessig S, Rishniw M, et al.: 2006, Adherent and invasive *Escherichia coli* are associated with persistent bovine mastitis. *Vet Microbiol* 116:270–282.
18. Escobar-Páramo P, Clermont O, Blanc-Potard AB, et al.: 2004, A specific genetic background is required for acquisition and expression of virulence factors in *Escherichia coli*. *Mol Biol Evol* 21:1085–1094.
19. Ewing WH: 1986, The genus *Escherichia*. In: Edwards and Ewing's identification of enterobacteriaceae, 4th ed., pp. 93–134. Elsevier Science Publishers, New York, NY.
20. Fang W, Pyörälä S: 1996, Mastitis-causing *Escherichia coli*: serum sensitivity and susceptibility to selected antibacterials in milk. *J Dairy Sci* 79:76–82.
21. Fidock DA, McNicholas PA, Lehrbach PR: 1989, Nucleotide sequence of the F41 fimbriae subunit gene in *Escherichia coli* B41. *Nucleic Acids Res* 17:2849.
22. Harmon RJ, Eberhart RJ, Jasper DE, et al.: 1990, Microbiological procedures for the diagnosis of bovine udder infection, 3rd ed. National Mastitis Council, Arlington, VA.
23. Johnson JR, Stell AL: 2000, Extended virulence genotypes of *Escherichia coli* strains from patients with urosepsis in relation to phylogeny and host compromise. *J Infect Dis* 181:261–272.

24. Kaipainen T, Pohjanvirta T, Shpigel NY, et al.: 2002, Virulence factors of *Escherichia coli* isolated from bovine clinical mastitis. *Vet Microbiol* 85:37–46.
25. Kaper JB, Nataro JP, Mobley HL: 2004, Pathogenic *Escherichia coli*. *Nat Rev Microbiol* 2:123–140.
26. Kawano K, Okada M, Haga T, et al.: 2008, Relationship between pathogenicity for humans and stx genotype in Shiga toxin-producing *Escherichia coli* serotype O157. *Eur J Clin Microbiol Infect Dis* 27:227–232.
27. Khan A, Das SC, Ramamurthy T, et al.: 2002, Antibiotic resistance, virulence gene, and molecular profiles of Shiga toxin-producing *Escherichia coli* isolates from diverse sources in Calcutta, India. *J Clin Microbiol* 40:2009–2015.
28. Melchior MB, Vaarkamp H, Fink-Gremmels J: 2006, Biofilms: a role in recurrent mastitis infections? *Vet J* 171:398–407.
29. Nemeth J, Muckle CA, Gyles CL: 1994, In vitro comparison of bovine mastitis and fecal *Escherichia coli* isolates. *Vet Microbiol* 40:231–238.
30. Nemeth J, Muckle CA, Lo RY: 1991, Serum resistance and the traT gene in bovine mastitis-causing *Escherichia coli*. *Vet Microbiol* 28:343–351.
31. Ojeniyi B, Ahrens P, Meyling A: 1994, Detection of fimbrial and toxin genes in *Escherichia coli* and their prevalence in piglets with diarrhoea. The application of colony hybridization assay, polymerase chain reaction and phenotypic assays. *Zentralbl Veterinarmed B* 41:49–59.
32. Paton AW, Paton JC: 1998, Detection and characterization of Shiga toxigenic *Escherichia coli* by using multiplex PCR assays for *stx1*, *stx2*, *eaeA*, enterohemorrhagic *E. coli hlyA*, *rfb*_{O111}, and *rfb*_{O157}. *J Clin Microbiol* 36:598–602.
33. Pelkonen S, Finne J: 1987, A rapid turbidimetric assay for the study of serum sensitivity of *Escherichia coli*. *FEMS Microbiol Lett* 42:53–57.
34. Rangel P, Marin JM: 2009, Analysis of *Escherichia coli* isolated from bovine mastitic milk. *Pesq Vet Bras* 29:363–368.
35. Roosendaal B, Gaastra W, Graaf FK: 1984, The nucleotide sequence of the genes encoding the K99 subunit of enterotoxigenic *Escherichia coli*. *FEMS Microbiol Lett* 22: 253–258.
36. Salvadori MR, Valadares GF, da Silva Leite D, et al.: 2003, Virulence factors of *Escherichia coli* isolated from calves with diarrhea in Brazil. *Braz J Microbiol* 34:230–235.
37. Schroeder CM, Zhao C, DebRoy C, et al.: 2002, Antimicrobial resistance of *Escherichia coli* O157 isolated from humans, cattle, swine, and food. *Appl Environ Microbiol* 68:576–581.
38. Schultz C, Pool GJ, van Ketel R, et al.: 1994, Detection of enterotoxigenic *Escherichia coli* in stool samples by using non-radioactively labeled oligonucleotide DNA probes and PCR. *J Clin Microbiol* 32:2393–2397.
39. Seegers H, Fourichon C, Beaudeau F: 2003, Production effects related to mastitis and mastitis economics in dairy cattle herds. *Vet Res* 34:475–491.
40. Sethabutr O, Venkatesan M, Murphy GS, et al.: 1993, Detection of Shigellae and enteroinvasive *Escherichia coli* by amplification of the invasion plasmid antigen H DNA sequence in patients with dysentery. *J Infect Dis* 167:458–461.
41. Shpigel NY, Elazar S, Rosenshine I: 2008, Mammary pathogenic *Escherichia coli*. *Curr Opin Microbiol* 11:60–65.
42. So M, McCarthy BJ: 1980, Nucleotide sequence of the bacterial transposon Tn1681 encoding a heat-stable (ST) toxin and its identification in enterotoxigenic *Escherichia coli* strains. *Proc Natl Acad Sci U S A* 77:4011–4015.
43. Stepanović S, Cirković I, Ranin L, Svabić-Vlahović M: 2004, Biofilm formation by *Salmonella* spp. and *Listeria monocytogenes* on plastic surface. *Lett Appl Microbiol* 38:428–432.
44. Van Houdt R, Michiels CW: 2005, Role of bacterial cell surface structures in *Escherichia coli* biofilm formation. *Res Microbiol* 156:626–633.
45. Yamamoto S, Terai A, Yuri K, et al.: 1995, Detection of urovirulence factors in *Escherichia coli* by multiplex polymerase chain reaction. *FEMS Immunol Med Microbiol* 12:85–90.
46. Yamamoto T, Echeverria P: 1996, Detection of the enteroaggregative *Escherichia coli* heat-stable enterotoxin 1 gene sequences in enterotoxigenic *E. coli* strains pathogenic for humans. *Infect Immun* 64:1441–1445.
47. Yu J, Kaper JB: 1992, Cloning and characterization of the *eae* gene of enterohaemorrhagic *Escherichia coli* O157:H7. *Mol Microbiol* 6:411–417.